Severe asthma: future treatments
- 20 April 2012
- journal article
- review article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 42 (5), 706-711
- https://doi.org/10.1111/j.1365-2222.2012.03965.x
Abstract
Patients with severe refractory asthma have not achieved asthma control, even with high doses of ICS, usually in combination with LABAs and other maintenance treatments. The most promising approaches currently under investigation are those which reduce airway eosinophils in patients with severe refractory asthma and a persisting airway eosinophilia. Monoclonal antibodies against IL‐5 have been shown to improve lung function, improve asthma control, reduce exacerbation risk and allow reduction or elimination of maintenance oral corticosteroids in this subset of patients. Bronchial thermoplasty may provide benefit in improving control and reducing exacerbations in selected patients. The addition of the muscarinic antagonist, tiotropium also improves airflow obstruction, but its benefit on exacerbation risk is not yet established. Other developments being evaluated in severe refractory asthma are CXCR2 antagonists in patients with a persisting neutrophilic airway inflammation, and CRTh2 antagonists, both of which are small molecule antagonists, and hMabs against IL4 and IL‐13. Finally, other approaches to reduce receptor numbers, using inhaled anti‐sense, has shown to reduce allergen‐induced airway eosinophilia, and combining different anti‐sense against different targets may become a feasible treatment option. A variety of new treatment options are being investigated to help improve overall asthma control in patients with severe refractory asthma. These include medications to optimize lung function; bronchial thermoplasty to reduce airway smooth muscle in central airways; and those which target specific inflammatory cells or receptors of inflammatory mediators. Patients with severe refractory asthma have the greatest unmet treatment needs to improve asthma control and reduce exacerbation risk. New treatment approaches have been identified which will benefit subsets of these patients. Phenotyping patients is necessary to select those likely to benefit.Keywords
This publication has 46 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthmaClinical and Experimental Allergy, 2011
- British guidelines on the management of asthma: what's new for 2011?Thorax, 2011
- Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)Thorax, 2010
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaThe New England Journal of Medicine, 2010
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProceedings of the National Academy of Sciences of the United States of America, 2007
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001